Jorge Malheiro1, Sandra Tafulo2, Leonídio Dias3, La Salete Martins4, Isabel Fonseca5, Idalina Beirão6, António Castro-Henriques7, António Cabrita8. 1. Nephrology and Kidney Transplantation Department, Hospital de Santo António, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal; Unit for Multidisciplinary Investigation in Biomedicine (UMIB), ICBAS - Universidade do Porto, Rua de Jorge Viterbo Ferreira no. 228, 4050-313 Porto, Portugal. Electronic address: jjorgemalheiro@gmail.com. 2. Centro do Sangue e Transplantação do Porto, Rua de Bolama no. 133, 4200-139 Porto, Portugal. Electronic address: Sandra.Tafulo@ipst.min-saude.pt. 3. Nephrology and Kidney Transplantation Department, Hospital de Santo António, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal. Electronic address: leonidiodias@sapo.pt. 4. Nephrology and Kidney Transplantation Department, Hospital de Santo António, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal; Unit for Multidisciplinary Investigation in Biomedicine (UMIB), ICBAS - Universidade do Porto, Rua de Jorge Viterbo Ferreira no. 228, 4050-313 Porto, Portugal. Electronic address: lasalet@gmail.com. 5. Nephrology and Kidney Transplantation Department, Hospital de Santo António, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal; Unit for Multidisciplinary Investigation in Biomedicine (UMIB), ICBAS - Universidade do Porto, Rua de Jorge Viterbo Ferreira no. 228, 4050-313 Porto, Portugal. Electronic address: isabelf27@gmail.com. 6. Nephrology and Kidney Transplantation Department, Hospital de Santo António, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal; Unit for Multidisciplinary Investigation in Biomedicine (UMIB), ICBAS - Universidade do Porto, Rua de Jorge Viterbo Ferreira no. 228, 4050-313 Porto, Portugal. Electronic address: idalina.m.b@gmail.com. 7. Nephrology and Kidney Transplantation Department, Hospital de Santo António, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal; Unit for Multidisciplinary Investigation in Biomedicine (UMIB), ICBAS - Universidade do Porto, Rua de Jorge Viterbo Ferreira no. 228, 4050-313 Porto, Portugal. Electronic address: antonioach@hotmail.com. 8. Nephrology and Kidney Transplantation Department, Hospital de Santo António, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal. Electronic address: acabrita.nefrologia@chporto.min-saude.pt.
Abstract
BACKGROUND: The relevance of preformed donor specific antibodies (DSA) detected by Luminex assays, with a negative complement-dependent cytotoxicity (CDC) crossmatch, remains unsettled in kidney transplantation (KT). We aimed to analyze the impact of preformed DSA characteristics on kidney graft outcomes. METHODS: In 462 patients that received a kidney graft in our unit, between 2007 and 2012, pre-transplant sera were analyzed by Luminex screening assay to determine the presence of anti-human leukocyte antigen (HLA) antibodies and single-antigen bead assay [positive if mean fluorescence intensity (MFI) ≥ 1000] to assign anti-HLA specificities. RESULTS: Anti-HLA antibodies were present in 95 patients (20.6%), but only 40 (8.7%) had DSA. Antibody-mediated rejection (AMR) at 1-year was higher in patients with DSA (35.0%) than in those without them (0.9%) (P < 0.001). Only DSA with a MFI of >3000 were significantly associated with AMR occurrence. Receiver operator curves revealed that a MFI of >4900 in the highest DSA bead had a high sensitivity (85.7%) and that the sum of all DSA beads MFI > 11,000 had a high specificity (92.3%) for AMR prediction. Anti-thymocyte globulin versus basiliximab induction was more frequent in DSA+ AMR- (65.4%) versus DSA+ AMR+ (34.6%) patients (P = 0.072). Five-year censored graft survival was lower in DSA+ than in DSA- patients (respectively, 84.8% versus 94.9%, P = 0.006), although survival was only reduced in DSA+ AMR+ (68.8%) versus DSA+ AMR- (96.0%) patients (P = 0.038). CONCLUSIONS: Preformed DSA is associated with kidney graft loss, in relation with AMR occurrence. DSA strength may be used to improve immunological risk stratification of sensitized patients and their clinical management.
BACKGROUND: The relevance of preformed donor specific antibodies (DSA) detected by Luminex assays, with a negative complement-dependent cytotoxicity (CDC) crossmatch, remains unsettled in kidney transplantation (KT). We aimed to analyze the impact of preformed DSA characteristics on kidney graft outcomes. METHODS: In 462 patients that received a kidney graft in our unit, between 2007 and 2012, pre-transplant sera were analyzed by Luminex screening assay to determine the presence of anti-human leukocyte antigen (HLA) antibodies and single-antigen bead assay [positive if mean fluorescence intensity (MFI) ≥ 1000] to assign anti-HLA specificities. RESULTS: Anti-HLA antibodies were present in 95 patients (20.6%), but only 40 (8.7%) had DSA. Antibody-mediated rejection (AMR) at 1-year was higher in patients with DSA (35.0%) than in those without them (0.9%) (P < 0.001). Only DSA with a MFI of >3000 were significantly associated with AMR occurrence. Receiver operator curves revealed that a MFI of >4900 in the highest DSA bead had a high sensitivity (85.7%) and that the sum of all DSA beads MFI > 11,000 had a high specificity (92.3%) for AMR prediction. Anti-thymocyte globulin versus basiliximab induction was more frequent in DSA+ AMR- (65.4%) versus DSA+ AMR+ (34.6%) patients (P = 0.072). Five-year censored graft survival was lower in DSA+ than in DSA- patients (respectively, 84.8% versus 94.9%, P = 0.006), although survival was only reduced in DSA+ AMR+ (68.8%) versus DSA+ AMR- (96.0%) patients (P = 0.038). CONCLUSIONS: Preformed DSA is associated with kidney graft loss, in relation with AMR occurrence. DSA strength may be used to improve immunological risk stratification of sensitized patients and their clinical management.
Authors: Alexander Kaltenborn; Almut Nolte; Ysabell Schwager; Simon A Littbarski; Nikos Emmanouilidis; Viktor Arelin; Jürgen Klempnauer; Harald Schrem Journal: Langenbecks Arch Surg Date: 2016-08-09 Impact factor: 3.445
Authors: Marcos Vinicius de Sousa; Ana Claudia Gonçalez; Ricardo de Lima Zollner; Marilda Mazzali Journal: Ann Transplant Date: 2018-07-06 Impact factor: 1.530
Authors: Nicole Wittenbrink; Sabrina Herrmann; Arturo Blazquez-Navarro; Chris Bauer; Eric Lindberg; Kerstin Wolk; Robert Sabat; Petra Reinke; Birgit Sawitzki; Oliver Thomusch; Christian Hugo; Nina Babel; Harald Seitz; Michal Or-Guil Journal: BMC Immunol Date: 2019-04-27 Impact factor: 3.615
Authors: Mason Phillpott; Sunil Daga; Rob Higgins; David Lowe; Nithya Krishnan; Daniel Zehnder; David Briggs; Natalia Khovanova Journal: Transpl Int Date: 2022-04-11 Impact factor: 3.842
Authors: Juan Molina; Ana Navas; María-Luisa Agüera; Cristian Rodelo-Haad; Corona Alonso; Alberto Rodríguez-Benot; Pedro Aljama; Rafael Solana Journal: Front Immunol Date: 2017-10-31 Impact factor: 7.561